212 related articles for article (PubMed ID: 24903453)
1. Clinical value of visually identifiable 18F-fluorodeoxyglucose uptake in primary papillary thyroid microcarcinoma.
Hwang SO; Lee SW; Kang JK; Choi HH; Kim WW; Park HY; Jung JH
Otolaryngol Head Neck Surg; 2014 Sep; 151(3):415-20. PubMed ID: 24903453
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
3. Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.
Yoon S; An YS; Lee SJ; So EY; Kim JH; Chung YS; Yoon JK
Medicine (Baltimore); 2015 Dec; 94(48):e2063. PubMed ID: 26632889
[TBL] [Abstract][Full Text] [Related]
4. Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor.
Yun M; Noh TW; Cho A; Choi YJ; Hong SW; Park CS; Lee JD; Kim CK
J Clin Endocrinol Metab; 2010 Jul; 95(7):3182-8. PubMed ID: 20427505
[TBL] [Abstract][Full Text] [Related]
5. Analysis of predictability of F-18 fluorodeoxyglucose-PET/CT in the recurrence of papillary thyroid carcinoma.
Kim SK; So Y; Chung HW; Yoo YB; Park KS; Hwang TS; Kim B; Lee WW
Cancer Med; 2016 Oct; 5(10):2756-2762. PubMed ID: 27539659
[TBL] [Abstract][Full Text] [Related]
6. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of primary papillary thyroid carcinoma with false-negative findings on initial (18)F-FDG PET/CT.
Choi JW; Yoon YH; Yoon YH; Kim SM; Koo BS
Ann Surg Oncol; 2011 May; 18(5):1306-11. PubMed ID: 21140231
[TBL] [Abstract][Full Text] [Related]
8. Prediction of central lymph node metastasis from papillary thyroid microcarcinoma by 18F-fluorodeoxyglucose PET/CT and ultrasonography.
Byun BH; Jeong UG; Hong SP; Min JJ; Chong A; Song HC; Bom HS
Ann Nucl Med; 2012 Jul; 26(6):471-7. PubMed ID: 22467230
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma.
Kim BS; Kim SJ; Kim IJ; Pak K; Kim K
Thyroid; 2012 Jul; 22(7):725-9. PubMed ID: 22524470
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.
Kim H; Na KJ; Choi JH; Ahn BC; Ahn D; Sohn JH
Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1569-76. PubMed ID: 25971994
[TBL] [Abstract][Full Text] [Related]
11. Number of central lymph node metastasis for predicting lateral lymph node metastasis in papillary thyroid microcarcinoma.
Zeng RC; Zhang W; Gao EL; Cheng P; Huang GL; Zhang XH; Li Q
Head Neck; 2014 Jan; 36(1):101-6. PubMed ID: 23900787
[TBL] [Abstract][Full Text] [Related]
12. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
13. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
14. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
15. Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection.
Chung YS; Kim JY; Bae JS; Song BJ; Kim JS; Jeon HM; Jeong SS; Kim EK; Park WC
Thyroid; 2009 Mar; 19(3):241-6. PubMed ID: 19265495
[TBL] [Abstract][Full Text] [Related]
16. Sonographic features of papillary thyroid microcarcinoma predicting high-volume central neck lymph node metastasis.
Huang XP; Ye TT; Zhang L; Liu RF; Lai XJ; Wang L; Yang M; Zhang B; Li XY; Liu ZW; Xia Y; Jiang YX
Surg Oncol; 2018 Jun; 27(2):172-176. PubMed ID: 29937168
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for central neck lymph node metastasis of clinically noninvasive, node-negative papillary thyroid microcarcinoma.
Park JP; Roh JL; Lee JH; Baek JH; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Am J Surg; 2014 Sep; 208(3):412-8. PubMed ID: 24602323
[TBL] [Abstract][Full Text] [Related]
18. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT.
Choi JS; Kim J; Kwak JY; Kim MJ; Chang HS; Kim EK
AJR Am J Roentgenol; 2009 Sep; 193(3):871-8. PubMed ID: 19696304
[TBL] [Abstract][Full Text] [Related]
19. Preoperative Prediction of Cervical Lymph Node Metastasis Using Primary Tumor SUVmax on 18F-FDG PET/CT in Patients with Papillary Thyroid Carcinoma.
Jung JH; Kim CY; Son SH; Kim DH; Jeong SY; Lee SW; Lee J; Ahn BC
PLoS One; 2015; 10(12):e0144152. PubMed ID: 26636824
[TBL] [Abstract][Full Text] [Related]
20. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma.
Kim TY; Kim WB; Ryu JS; Gong G; Hong SJ; Shong YK
Laryngoscope; 2005 Jun; 115(6):1074-8. PubMed ID: 15933524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
